| Literature DB >> 33278965 |
Han Sol Lee1, Nae-Won Kang2, Hyelim Kim3, Dong Hyun Kim1, Jung-Woo Chae1, Wonhwa Lee4, Gyu Yong Song1, Cheong-Weon Cho1, Dae-Duk Kim2, Jae-Young Lee5.
Abstract
Chondroitin sulfate-hybridized zein nanoparticles (zein/CS NPs) were developed for targeted delivery of docetaxel, which exhibited mean diameters of 157.8 ± 3.6 nm and docetaxel encapsulation efficiency of 64.2 ± 1.9 %. Docetaxel was released from the NPs in a sustained manner (∼72 h), following first-order kinetics. The zein/CS NPs showed improved colloidal stability, maintaining the initial size in serum for 12 h. The pre-treatment of CS reduced the uptake efficiency of the NPs by 23 % in PC-3 cells, suggesting the involvement of CD44-mediated uptake mechanism. The NPs showed 2.79-fold lower IC50 values than free docetaxel. Enhanced tumor accumulation of the NPs was confirmed in PC-3 xenograft mice by near-infrared fluorescence imaging (35.3-fold, versus free Cy5.5). The NPs exhibited improved pharmacokinetic properties (9.5-fold longer terminal half-life, versus free docetaxel) and anti-tumor efficacy comparable to Taxotere with negligible systemic toxicity, suggesting zein/CS NPs could be a promising nanoplatform for targeted cancer therapy.Entities:
Keywords: CD44 receptor; Chondroitin sulfate; Chondroitin sulfate (PubChem CID: 24766); Docetaxel; Docetaxel (PubChem CID: 148124); Nanoparticles; Tumor-targeting; Zein; Zein (PubChem SID: 135291755)
Mesh：
Substances：
Year: 2020 PMID： 33278965 DOI： 10.1016/j.carbpol.2020.117187
Source DB: PubMed Journal: Carbohydr Polym ISSN： 0144-8617 Impact factor: 9.381